|
|
 |
|
Management Biographies |
|
|
 |
|
|
RODNEY W.
UNSWORTH
Group Vice President and President, Asia-Pacific Region
Schering-Plough Corporation
Rodney W. Unsworth is group vice president and president,
Asia-Pacific Region, of Schering-Plough Corporation.
Unsworth has held various senior level international management roles
in the pharmaceutical industry with Asia-Pacific and Australian companies.
Before joining Schering-Plough, he was actively involved in assisting
small medical research-based companies, including ObjectiVision Pty.
Ltd. and BioDiem Ltd. in Australia, to commercialize their innovation
potential. Prior to this position, he served as regional president,
Asia-Pacific Region, for the former Pharmacia Corporation.
He has a degree in pharmacy from the Victorian College of Pharmacy,
Australia.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
